SproutNews logo

Testosterone Lawsuit Update: Bellwether Case Selection Process Being Disputed in AndroGel MDL

August 31, 2015 – – Banville Law reports on an update in the pending testosterone litigation involving AbbVie, Auxilium, Pfizer and other pharmaceutical companies.

Nearly 2,000 lawsuits have been filed in relation to allegedly dangerous side effects of testosterone replacement therapy (TRT) supplements since the Multidistrict Litigation (MDL) was established in the US District Court for the Northern District of Illinois.

The first bellwether trial is scheduled to begin on October 1st, 2016 and several other trials are scheduled to commence shortly thereafter. However, while the dates of the initial trials have been set, the specific cases that will be tried have not been chosen yet.

Parties from both sides of the litigation discussed the selection process for the bellwether cases in a recent status meeting held on August 14th. According to official minutes from the status conference, defendant AbbVie (maker of AndroGel) proposed that the court select 32 cases for discovery. After the discovery process is complete, AbbVie proposes that plaintiffs and defendants then agree on six cases (from the pool of 32) to go to trial.

Conversely, plaintiffs proposed that both sides of the litigation submit a list of 16 potential cases for selection and that the court choose six cases for the bellwether trials.

Low T Litigation: The Importance of Bellwether Trial Selection

“The selection of bellwether trials will be a key part of this litigation,” commented Laurence Banville, Esq. of Banville Law.

“The outcomes of these initial trials will set the pace for the remainder of the MDL and will help parties on both sides of the litigation to make crucial decisions going forward,” continued Banville.

Banville is a sponsor of online resource center LowTestosteroneCase.com, which provides information on the testosterone litigation, as well as access to legal representation for those wishing to file a complaint.

Please direct all questions about this press release and about pending testosterone litigation to Laurence Banville, Esq. at 888-478-9711.


Contact Banville Law:

Laurence Banville, Esq.
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60003787

Go Top